137 related articles for article (PubMed ID: 37737015)
1. Canonical Kaiso target genes define a functional signature that associates with breast cancer survival and the invasive lobular carcinoma histological type.
Sijnesael T; Richard F; Rätze MA; Koorman T; Bassey-Archibong B; Rohof C; Daniel J; Desmedt C; Derksen PW
J Pathol; 2023 Dec; 261(4):477-489. PubMed ID: 37737015
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Kaiso expression is associated with high grade and triple-negative invasive breast cancer.
Vermeulen JF; van de Ven RA; Ercan C; van der Groep P; van der Wall E; Bult P; Christgen M; Lehmann U; Daniel J; van Diest PJ; Derksen PW
PLoS One; 2012; 7(5):e37864. PubMed ID: 22662240
[TBL] [Abstract][Full Text] [Related]
3. Nuclear p120-catenin regulates the anoikis resistance of mouse lobular breast cancer cells through Kaiso-dependent Wnt11 expression.
van de Ven RA; Tenhagen M; Meuleman W; van Riel JJ; Schackmann RC; Derksen PW
Dis Model Mech; 2015 Apr; 8(4):373-84. PubMed ID: 25713299
[TBL] [Abstract][Full Text] [Related]
4. Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.
Rätze MAK; Koorman T; Sijnesael T; Bassey-Archibong B; van de Ven R; Enserink L; Visser D; Jaksani S; Viciano I; Bakker ERM; Richard F; Tutt A; O'Leary L; Fitzpatrick A; Roca-Cusachs P; van Diest PJ; Desmedt C; Daniel JM; Isacke CM; Derksen PWB
Oncogene; 2022 May; 41(21):2932-2944. PubMed ID: 35437308
[TBL] [Abstract][Full Text] [Related]
5. αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer.
de Groot JS; Ratze MA; van Amersfoort M; Eisemann T; Vlug EJ; Niklaas MT; Chin SF; Caldas C; van Diest PJ; Jonkers J; de Rooij J; Derksen PW
J Pathol; 2018 Aug; 245(4):456-467. PubMed ID: 29774524
[TBL] [Abstract][Full Text] [Related]
6. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
7. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
[TBL] [Abstract][Full Text] [Related]
8. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
9. [Expression pattern of E-cadherin and p120-catenin in infiltrating lobular carcinoma and ductal carcinoma of the breast and its significance].
Li L; Bi XF; Xu X; Liu XY; Shen GH; Guo L; Yuan YL; Wang F; Wang MR; Yang HY
Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):273-7. PubMed ID: 20510078
[TBL] [Abstract][Full Text] [Related]
10. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes.
Engstrøm MJ; Opdahl S; Vatten LJ; Haugen OA; Bofin AM
Histopathology; 2015 Feb; 66(3):409-19. PubMed ID: 25283075
[TBL] [Abstract][Full Text] [Related]
11. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
12. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
13. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
[TBL] [Abstract][Full Text] [Related]
14. Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma.
Tasdemir N; Ding K; Savariau L; Levine KM; Du T; Elangovan A; Bossart EA; Lee AV; Davidson NE; Oesterreich S
Sci Rep; 2020 Jul; 10(1):11487. PubMed ID: 32661241
[TBL] [Abstract][Full Text] [Related]
15. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.
Turashvili G; Bouchal J; Baumforth K; Wei W; Dziechciarkova M; Ehrmann J; Klein J; Fridman E; Skarda J; Srovnal J; Hajduch M; Murray P; Kolar Z
BMC Cancer; 2007 Mar; 7():55. PubMed ID: 17389037
[TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
17. Effect of histological breast cancer subtypes invasive lobular versus non-special type on survival in early intermediate-to-high-risk breast carcinoma: results from the SUCCESS trials.
Dayan D; Lukac S; Rack B; Ebner F; Fink V; Leinert E; Veselinovic K; Schütze S; El Taie Z; Janni W; Friedl TWP
Breast Cancer Res; 2023 Dec; 25(1):153. PubMed ID: 38098086
[TBL] [Abstract][Full Text] [Related]
18. Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast.
Arps DP; Healy P; Zhao L; Kleer CG; Pang JC
Breast Cancer Res Treat; 2013 Apr; 138(3):719-26. PubMed ID: 23535842
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
Ciriello G; Gatza ML; Beck AH; Wilkerson MD; Rhie SK; Pastore A; Zhang H; McLellan M; Yau C; Kandoth C; Bowlby R; Shen H; Hayat S; Fieldhouse R; Lester SC; Tse GM; Factor RE; Collins LC; Allison KH; Chen YY; Jensen K; Johnson NB; Oesterreich S; Mills GB; Cherniack AD; Robertson G; Benz C; Sander C; Laird PW; Hoadley KA; King TA; ; Perou CM
Cell; 2015 Oct; 163(2):506-19. PubMed ID: 26451490
[TBL] [Abstract][Full Text] [Related]
20. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
Lips EH; Mukhtar RA; Yau C; de Ronde JJ; Livasy C; Carey LA; Loo CE; Vrancken-Peeters MJ; Sonke GS; Berry DA; Van't Veer LJ; Esserman LJ; Wesseling J; Rodenhuis S; Shelley Hwang E;
Breast Cancer Res Treat; 2012 Nov; 136(1):35-43. PubMed ID: 22961065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
